Skip to content

Open -Label,Cross Over Trail Evaluating the Glycemic Impact of Peach Varieties in Healthy Adullts

Open -Label,Cross Over Trail Evaluating the Glycemic Impact of Peach Varieties in Healthy Adullts

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07015788
Enrollment
16
Registered
2025-06-11
Start date
2025-06-30
Completion date
2025-09-30
Last updated
2025-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Glucoe

Keywords

glycemic index, glycemic load

Brief summary

This study aims to evaluate the effect of different peach varieties on the glycemic index (GI) in healthy adult participants. While peaches are generally classified as low-GI fruits, variations in sugar composition, fiber content, and ripeness among different cultivars may influence their glycemic response. By assessing and comparing the GI values of several commonly consumed peach varieties, this trial seeks to provide more precise dietary recommendations for glycemic control and support better fruit selection for individuals managing blood glucose levels.

Detailed description

This study aims to evaluate the effect of different peach varieties on the glycemic index (GI) in healthy adult participants. While peaches are generally classified as low-GI fruits, variations in sugar composition, fiber content, and ripeness among different cultivars may influence their glycemic response. By assessing and comparing the GI values of several commonly consumed peach varieties, this trial seeks to provide more precise dietary recommendations for glycemic control and support better fruit selection for individuals managing blood glucose levels.

Interventions

OTHEREARLY GRAND

Participants will consume a standardized portion of peach variety A containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.

OTHERSPRING CREST PEACH

Participants will consume a standardized portion of peach variety B containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.

OTHERINDIAN BLOOD

Participants will consume a standardized portion of peach variety C containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.

Sponsors

Rehman Medical Institute - RMI
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

• Healthy male and female adults aged 18-50 years * BMI between 18.5-24.9 kg/m² * Normal fasting blood glucose (\<100 mg/dL) * Willingness to adhere to the study protocol

Exclusion criteria

• Diagnosed diabetes, metabolic syndrome, or any glucose metabolism disorder * Use of medications or supplements that affect glucose levels * Allergy to peaches or intolerance to test/reference foods * Pregnant or breastfeeding women * Smoking or use of recreational drugs

Design outcomes

Primary

MeasureTime frameDescription
Glycemic Index2 hours post-consumption (per intervention)Participants will consume a standardized portion of a peach variety containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.

Secondary

MeasureTime frameDescription
Incremental Area Under the Curve (iAUC) for Blood Glucose0-120 minutes post-consumptionThe iAUC will be calculated for each intervention using the trapezoidal method, excluding values below baseline. This helps quantify the glycemic response.
Peak Blood Glucose Concentration0-120 minutes post-consumptionThe highest recorded blood glucose concentration during the 2-hour postprandial period following consumption of each intervention.

Countries

Pakistan

Contacts

Primary ContactNaseer Ahmed
dr.naseer99@mail.com03305485960

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026